Literature DB >> 9285227

Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.

A H Briggs1, D E Wonderling, C Z Mooney.   

Abstract

The statistic of interest in the economic evaluation of health care interventions is the incremental cost effectiveness ratio (ICER), which is defined as the difference in cost between two treatment interventions over the difference in their effect. Where patient-specific data on costs and health outcomes are available, it is natural to attempt to quantify uncertainty in the estimated ICER using confidence intervals. Recent articles have focused on parametric methods for constructing confidence intervals. In this paper, we describe the construction of non-parametric bootstrap confidence intervals. The advantage of such intervals is that they do not depend on parametric assumptions of the sampling distribution of the ICER. We present a detailed description of the non-parametric bootstrap applied to data from a clinical trial, in order to demonstrate the strengths and weaknesses of the approach. By examining the bootstrap confidence limits successively as the number of bootstrap replications increases, we conclude that percentile bootstrap confidence interval methods provide a promising approach to estimating the uncertainty of ICER point estimates. However, successive bootstrap estimates of bias and standard error suggests that these may be unstable; accordingly, we strongly recommend a cautious interpretation of such estimates.

Entities:  

Mesh:

Year:  1997        PMID: 9285227     DOI: 10.1002/(sici)1099-1050(199707)6:4<327::aid-hec282>3.0.co;2-w

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  235 in total

1.  Handling uncertainty in economic evaluations of healthcare interventions.

Authors:  A H Briggs; A M Gray
Journal:  BMJ       Date:  1999-09-04

2.  Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.

Authors:  Martin E Backhouse
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Advantages of laparoscopic resection for ileocolic Crohn's disease. Improved outcomes and reduced costs.

Authors:  T M Young-Fadok; K HallLong; E J McConnell; G Gomez Rey; R L Cabanela
Journal:  Surg Endosc       Date:  2001-04-03       Impact factor: 4.584

4.  Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial.

Authors:  Tazeen H Jafar; Muhammad Islam; Rasool Bux; Neil Poulter; Juanita Hatcher; Nish Chaturvedi; Shah Ebrahim; Peter Cosgrove
Journal:  Circulation       Date:  2011-09-19       Impact factor: 29.690

Review 5.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

6.  Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT.

Authors:  Rahul Bhatnagar; Ramon Luengo-Fernandez; Brennan C Kahan; Najib M Rahman; Robert F Miller; Nick A Maskell
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

7.  Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina.

Authors:  Federico Augustovski; Martín Chaparro; Alfredo Palacios; Lizheng Shi; Andrea Beratarrechea; Vilma Irazola; Adolfo Rubinstein; Katherine Mills; Jiang He; Andrés Pichon Riviere
Journal:  Value Health       Date:  2018-08-30       Impact factor: 5.725

8.  Future challenges for the economic evaluation of healthcare: patient preferences, risk attitudes and beyond.

Authors:  John F P Bridges
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

9.  Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data.

Authors:  Bo Standaert; Janet Goldstone; Z John Lu; Moshe Haim Erder; John Liu Yin
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

10.  Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial.

Authors:  D Max Crowley; Damon E Jones; Donna L Coffman; Mark T Greenberg
Journal:  Prev Med       Date:  2014-02-09       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.